Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.09
EBS's Cash-to-Debt is ranked lower than
82% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. EBS: 1.09 )
Ranked among companies with meaningful Cash-to-Debt only.
EBS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.52  Med: 2.03 Max: N/A
Current: 1.09
Equity-to-Asset 0.64
EBS's Equity-to-Asset is ranked lower than
56% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. EBS: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
EBS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.68 Max: 0.81
Current: 0.64
0.33
0.81
Interest Coverage 10.92
EBS's Interest Coverage is ranked lower than
85% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. EBS: 10.92 )
Ranked among companies with meaningful Interest Coverage only.
EBS' s Interest Coverage Range Over the Past 10 Years
Min: 10.82  Med: 2815.62 Max: N/A
Current: 10.92
Piotroski F-Score: 4
Altman Z-Score: 3.91
Beneish M-Score: -1.80
WACC vs ROIC
9.51%
9.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 17.10
EBS's Operating Margin % is ranked higher than
84% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. EBS: 17.10 )
Ranked among companies with meaningful Operating Margin % only.
EBS' s Operating Margin % Range Over the Past 10 Years
Min: 10.63  Med: 17.6 Max: 28.92
Current: 17.1
10.63
28.92
Net Margin % 11.36
EBS's Net Margin % is ranked higher than
82% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. EBS: 11.36 )
Ranked among companies with meaningful Net Margin % only.
EBS' s Net Margin % Range Over the Past 10 Years
Min: 8.35  Med: 11.09 Max: 18.07
Current: 11.36
8.35
18.07
ROE % 9.42
EBS's ROE % is ranked higher than
84% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. EBS: 9.42 )
Ranked among companies with meaningful ROE % only.
EBS' s ROE % Range Over the Past 10 Years
Min: 5.5  Med: 9.3 Max: 16.93
Current: 9.42
5.5
16.93
ROA % 5.89
EBS's ROA % is ranked higher than
85% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. EBS: 5.89 )
Ranked among companies with meaningful ROA % only.
EBS' s ROA % Range Over the Past 10 Years
Min: 4.23  Med: 5.8 Max: 12.24
Current: 5.89
4.23
12.24
ROC (Joel Greenblatt) % 19.06
EBS's ROC (Joel Greenblatt) % is ranked higher than
84% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. EBS: 19.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EBS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 11.5  Med: 24.3 Max: 41.28
Current: 19.06
11.5
41.28
3-Year Revenue Growth Rate 5.20
EBS's 3-Year Revenue Growth Rate is ranked higher than
50% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. EBS: 5.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EBS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.1  Med: 8.8 Max: 31.3
Current: 5.2
-1.1
31.3
3-Year EBITDA Growth Rate 20.50
EBS's 3-Year EBITDA Growth Rate is ranked higher than
72% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. EBS: 20.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EBS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.4 Max: 46.8
Current: 20.5
0
46.8
3-Year EPS without NRI Growth Rate 16.70
EBS's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. EBS: 16.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EBS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.7  Med: 6.65 Max: 61.7
Current: 16.7
-26.7
61.7
GuruFocus has detected 3 Warning Signs with Emergent BioSolutions Inc $EBS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EBS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

EBS Guru Trades in Q2 2016

Jim Simons 1,274,211 sh (+14.50%)
Joel Greenblatt 465,311 sh (+4.86%)
Ken Fisher 467,770 sh (+2.19%)
Paul Tudor Jones 16,200 sh (-34.23%)
» More
Q3 2016

EBS Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
Ken Fisher 453,870 sh (-2.97%)
Jim Simons 1,178,111 sh (-7.54%)
Joel Greenblatt 242,516 sh (-47.88%)
» More
Q4 2016

EBS Guru Trades in Q4 2016

Paul Tudor Jones 9,700 sh (New)
Ken Fisher 418,270 sh (-7.84%)
Jim Simons 883,511 sh (-25.01%)
Joel Greenblatt 165,519 sh (-31.75%)
» More
Q1 2017

EBS Guru Trades in Q1 2017

Ken Fisher 413,020 sh (-1.26%)
Jim Simons 702,711 sh (-20.46%)
Joel Greenblatt 120,168 sh (-27.40%)
Paul Tudor Jones 7,000 sh (-27.84%)
» More
» Details

Insider Trades

Latest Guru Trades with EBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:LOXO, NAS:DERM, NAS:CHRS, NAS:INVA, NAS:GBT, NAS:RGEN, NAS:FOLD, NAS:CORT, OTCPK:GNFTF, NAS:INSM, NAS:EPZM, NAS:PBYI, NAS:ARRY, NAS:XNCR, OTCPK:PFSCF, OTCPK:PHMMF, NAS:XLRN, NAS:BGNE, NAS:AIMT, NAS:FWP » details
Traded in other countries:ER4.Germany,
Headquarter Location:USA
Emergent BioSolutions Inc is a specialty biopharmaceutical company It develops, manufactures, and delivers a portfolio of medical countermeasures for government agencies in the areas of biological and chemical threats and emerging infectious diseases.

Emergent BioSolutions is a global biotechnology company that offers biopharmaceutical products to healthcare providers and governments. The company has two operating divisions: biodefense and biosciences. Its specialty biodefense division focuses on countermeasures that address public health threats. The U.S. government is the primary purchaser of these products and often provides substantial funding for their development. Emergent's biosciences business is primarily focused on hematology and oncology therapeutics, with a secondary focus on transplantation, infectious disease, and autoimmunity.

Top Ranked Articles about Emergent BioSolutions Inc

Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; Webcast Will be Available
Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore
Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA
Emergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call on May 4, 2017
Emergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botulism Antitoxin
Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic National Stockpile

GAITHERSBURG, Md., March 17, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (:EBS) today announced that it has signed a two-year contract with the Biomedical Advanced Research and Development Authority (BARDA), a division within the Office of the Assistant Secretary of Preparedness and Response, valued at $100 million for the delivery of BioThrax® (Anthrax Vaccine Adsorbed) to the Strategic National Stockpile (SNS). This contract satisfies BARDA's notice of intent to sole source BioThrax that was issued on December 8, 2016 and is separate from and in addition to the company’s $911 million BioThrax procurement contract with the Centers for Disease Control and Prevention (CDC). BioThrax pricing under this BARDA procurement contract is the same as BioThrax pricing under the CDC follow-on contract.
“Emergent is pleased to support BARDA in its efforts to enhance the nation’s preparedness against the threat of anthrax,” said Adam Havey, executive vice president and president biodefense division at Emergent BioSolutions. “Emergent is committed to developing and manufacturing preparedness solutions that address our customers’ needs to protect against a broad spectrum of public health threats.” Simultaneously with the execution of this procurement contract, the company signed a modification to its September 30, 2016 contract with BARDA for the development and procurement of NuThrax™ (anthrax vaccine adsorbed with CPG 7909 adjuvant), the company’s next generation anthrax vaccine candidate. The modification increases the number of doses of NuThrax to be delivered under the base period from two million to three million doses with a commensurate reduction in dose price for the initial deliveries. The modification also reduces the purchase price for doses to be procured during the option period by $100 million thereby reducing the total contract value to be up to $1.5 billion, from the previously disclosed $1.6 billion.  Contract HHSO100201700007C for the procurement of BioThrax and contract HHSO100201600030C for the advanced development and delivery of NuThrax have both been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, at the U.S. Department of Health and Human Services.  About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu. Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the total potential realizable value of the contract, our strategy, future operations, prospects, plans and objectives with respect to BioThrax and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates” and similar expressions, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax procurement under the contract and our manufacturing capabilities and strategies. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.
Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
[email protected]

Media Contact:
Tracey Schmitt Lintott
Senior Vice President, Global Public Affairs
240-631-3281
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 25.92
EBS's PE Ratio is ranked higher than
50% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. EBS: 25.92 )
Ranked among companies with meaningful PE Ratio only.
EBS' s PE Ratio Range Over the Past 10 Years
Min: 5.26  Med: 21.36 Max: 67.2
Current: 25.92
5.26
67.2
Forward PE Ratio 18.59
EBS's Forward PE Ratio is ranked lower than
55% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. EBS: 18.59 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 28.82
EBS's PE Ratio without NRI is ranked lower than
52% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. EBS: 28.82 )
Ranked among companies with meaningful PE Ratio without NRI only.
EBS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.26  Med: 20.33 Max: 67.2
Current: 28.82
5.26
67.2
PB Ratio 2.06
EBS's PB Ratio is ranked higher than
74% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. EBS: 2.06 )
Ranked among companies with meaningful PB Ratio only.
EBS' s PB Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.8 Max: 3.61
Current: 2.06
0.8
3.61
PS Ratio 2.83
EBS's PS Ratio is ranked higher than
82% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. EBS: 2.83 )
Ranked among companies with meaningful PS Ratio only.
EBS' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 2.23 Max: 4.1
Current: 2.83
0.77
4.1
Price-to-Operating-Cash-Flow 29.34
EBS's Price-to-Operating-Cash-Flow is ranked lower than
59% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. EBS: 29.34 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EBS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.79  Med: 13.46 Max: 97.72
Current: 29.34
2.79
97.72
EV-to-EBIT 13.70
EBS's EV-to-EBIT is ranked higher than
60% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. EBS: 13.70 )
Ranked among companies with meaningful EV-to-EBIT only.
EBS' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.9  Med: 11.9 Max: 38.3
Current: 13.7
1.9
38.3
EV-to-EBITDA 9.53
EBS's EV-to-EBITDA is ranked higher than
72% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. EBS: 9.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
EBS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.8  Med: 9.1 Max: 22
Current: 9.53
1.8
22
PEG Ratio 1.00
EBS's PEG Ratio is ranked higher than
69% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. EBS: 1.00 )
Ranked among companies with meaningful PEG Ratio only.
EBS' s PEG Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.91 Max: 85.06
Current: 1
0.52
85.06
Shiller PE Ratio 29.75
EBS's Shiller PE Ratio is ranked higher than
77% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. EBS: 29.75 )
Ranked among companies with meaningful Shiller PE Ratio only.
EBS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.28  Med: 28.64 Max: 40.87
Current: 29.75
15.28
40.87
Current Ratio 7.22
EBS's Current Ratio is ranked higher than
56% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. EBS: 7.22 )
Ranked among companies with meaningful Current Ratio only.
EBS' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 4.13 Max: 7.22
Current: 7.22
1.22
7.22
Quick Ratio 6.18
EBS's Quick Ratio is ranked higher than
53% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. EBS: 6.18 )
Ranked among companies with meaningful Quick Ratio only.
EBS' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 3.62 Max: 6.18
Current: 6.18
0.76
6.18
Days Inventory 187.70
EBS's Days Inventory is ranked lower than
71% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. EBS: 187.70 )
Ranked among companies with meaningful Days Inventory only.
EBS' s Days Inventory Range Over the Past 10 Years
Min: 87.55  Med: 134.7 Max: 214.89
Current: 187.7
87.55
214.89
Days Sales Outstanding 91.14
EBS's Days Sales Outstanding is ranked lower than
71% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. EBS: 91.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
EBS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.05  Med: 69.18 Max: 124.36
Current: 91.14
36.05
124.36
Days Payable 62.10
EBS's Days Payable is ranked higher than
63% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. EBS: 62.10 )
Ranked among companies with meaningful Days Payable only.
EBS' s Days Payable Range Over the Past 10 Years
Min: 62.1  Med: 162.25 Max: 350.8
Current: 62.1
62.1
350.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.40
EBS's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. EBS: -3.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EBS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.3  Med: -3.8 Max: -1.5
Current: -3.4
-13.3
-1.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 8.37
EBS's Price-to-Net-Current-Asset-Value is ranked lower than
64% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. EBS: 8.37 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EBS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.39  Med: 6.16 Max: 40.54
Current: 8.37
3.39
40.54
Price-to-Tangible-Book 2.30
EBS's Price-to-Tangible-Book is ranked higher than
76% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. EBS: 2.30 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EBS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.83  Med: 1.99 Max: 3.7
Current: 2.3
0.83
3.7
Price-to-Intrinsic-Value-Projected-FCF 2.21
EBS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. EBS: 2.21 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EBS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.06  Med: 1.74 Max: 3.38
Current: 2.21
1.06
3.38
Price-to-Median-PS-Value 1.26
EBS's Price-to-Median-PS-Value is ranked lower than
65% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. EBS: 1.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EBS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 0.97 Max: 1.9
Current: 1.26
0.35
1.9
Price-to-Peter-Lynch-Fair-Value 1.19
EBS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
67% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. EBS: 1.19 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
EBS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.22 Max: 7.19
Current: 1.19
0.57
7.19
Price-to-Graham-Number 1.71
EBS's Price-to-Graham-Number is ranked higher than
72% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. EBS: 1.71 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EBS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.48  Med: 1.26 Max: 2.57
Current: 1.71
0.48
2.57
Earnings Yield (Greenblatt) % 7.27
EBS's Earnings Yield (Greenblatt) % is ranked higher than
87% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. EBS: 7.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EBS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 8.4 Max: 51.8
Current: 7.27
2.6
51.8
Forward Rate of Return (Yacktman) % 25.49
EBS's Forward Rate of Return (Yacktman) % is ranked higher than
68% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. EBS: 25.49 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
EBS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -13.5  Med: 2.5 Max: 30.4
Current: 25.49
-13.5
30.4

More Statistics

Revenue (TTM) (Mil) $512.9
EPS (TTM) $ 1.18
Beta1.48
Short Percentage of Float10.21%
52-Week Range $24.47 - 41.91
Shares Outstanding (Mil)40.97

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 510 526
EPS ($) 1.63 1.96
EPS without NRI ($) 1.63 1.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for EBS

Headlines

Articles On GuruFocus.com
Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; W May 11 2017 
Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufac May 10 2017 
Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manuf May 09 2017 
Emergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call Apr 20 2017 
Emergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botuli Mar 31 2017 
Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic N Mar 17 2017 
Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemor Feb 13 2017 
Emergent BioSolutions to Release Fourth Quarter and Full Year 2016 Financial Results and Conduct a C Feb 09 2017 
Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum Anti Feb 01 2017 
Emergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for Large-S Jan 27 2017 

More From Other Websites
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : May... May 24 2017
ETFs with exposure to Emergent BioSolutions, Inc. : May 22, 2017 May 22 2017
Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 May 19 2017
Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT;... May 11 2017
Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and... May 10 2017
Edited Transcript of EBS earnings conference call or presentation 4-May-17 9:00pm GMT May 09 2017
Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and... May 09 2017
Emergent Biosolutions Inc. Moves Things Around, Still Sees Growth May 08 2017
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : May 8,... May 08 2017
Emergent Biosolutions beats 1Q profit forecasts May 04 2017
Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance May 04 2017
Emergent BioSolutions, Inc. – Value Analysis (NYSE:EBS) : April 27, 2017 Apr 27 2017
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : April... Apr 26 2017
Emergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call... Apr 20 2017
Emergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of... Mar 31 2017
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : March... Mar 20 2017
Emergent BioSolutions gets $100 million anthrax contract from feds Mar 20 2017
Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic... Mar 17 2017
Local drug company stocks react to Trump's proposed cuts to NIH, FDA Mar 16 2017
Blog Coverage Galapagos Announced New Phase-II Studies Led by Filgotinib Collaboration Partner... Mar 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)